Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Nuevolution Announces Formation of Strong Scientific Advisory Panel

Published: Thursday, March 14, 2013
Last Updated: Wednesday, March 13, 2013
Bookmark and Share
Company teams with scientific advisors to assist the progression of its internal drug discovery programs.

Nuevolution teams with key scientific advisors to assist the progression of its internal drug discovery programs within Inflammation and Oncology.

In June 2012, Nuevolution has announced the closing of a new financing round, and the plans to initiate internal drug discovery efforts.

Since then, Nuevolution has prioritized more than 30 high-value challenging targets for screening, which has been initiated.

The target prioritization and further program decisions have been made in close collaboration with the newly appointed advisors.

Professor Sir Marc Feldmann, Kennedy Institute, UK. Dr. Feldmann is a world-renowned scientist within immunology and a special interest in the fields of autoimmune diseases and the roles of cytokines.

He is recipient of numerous honors and awards over the years and has pioneered the work on the development of antibodies against TNFα for the treatment of RA.

Professor Dr. Gordon B. Mills, MD Anderson Cancer Center, US. Dr. Mills is a world-leading scientist within oncology and professor and chair in the Department of Systems Biology in the Division of Cancer Medicine at the MD Anderson Cancer Center, where he holds the Olga Keith Wiess Distinguished University Chair in Cancer Medicine.

Dr. Mills is co-director of the Sheikh Khalifa bin Zayed Al Nahyan Institute for Personalized Cancer Therapy and director Kleberg Center for Molecular Markers.

He also serves as advisor for pre-clinical and clinical oncology studies supporting numerous pharmaceutical- and biotechnology companies.

Dr. Alan Collis, formerly Novartis and Aventis, US. Dr. Collis has 25 years of industry experience. He has a very strong track-record within chemistry, DMPK studies and pre-clinical candidate development.

He has served as head of section within oncology at Novartis and as a central member of their Oncology and Exploratory Chemistry leadership team.

At Aventis he served at their Review Board involved with recommendations from target selection through to phase IIb initiation within inflammation and CNS diseases.

“We are obviously delighted to receive support from such a strong and experienced advisory team to help us leverage our Chemetics® technology platform and plan and promote our own pipeline” said Thomas Franch, CSO of Nuevolution.

Franch continued, “We look forward to working with Marc, Gordon and Alan and we are confident that they will help accelerate our discovery projects and provide substantial value to our programs.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Professor Paul Workman Joins Nuevolution as Scientific Advisor
Professor Workman brings a vast knowledge and expertise within the oncology field.
Friday, July 11, 2014
Brian Zambrowicz Joins Nuevolution as Director and Senior Scientific Advisor
Company also announces other Board of Directors.
Thursday, May 22, 2014
Nuevolution, Merck License Agreement
Agreement for small molecule compounds targeting an undisclosed intracellular target for use as leads in Merck’s drug discovery and development.
Friday, February 21, 2014
Nuevolution Announces Technology Licensing Agreement
Agreement with Novartis for use of Nuevolution’s Chemetics® technology.
Friday, January 10, 2014
Nuevolution Appoints Ton Berkien as Chief Business Officer
Ton Berkien will join the company on January 1, 2014.
Tuesday, December 10, 2013
Nuevolution A/S Raises € 11 Million in New Financing Round
New financing round will enable Nuevolution to transform its current business model.
Friday, June 22, 2012
Nuevolution Announces Collaboration in Drug Discovery with Boehringer Ingelheim
Partnership to use Nuevolution's Chemetics® technology for lead discovery.
Wednesday, September 21, 2011
Nuevolution Enters Lead Discovery Collaboration in the Field of Epigenetic Disorders
A consortium has been established with the objective of identifying and developing novel small molecule drugs against epigenetic factors.
Thursday, October 07, 2010
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!